CanSino (Convidecia) in COVID-19 prophylaxis (excluding children) - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias symptomatic Covid-19detailed results CanSino phase 3, 2021 0.43 [0.30; 0.60]
0.43 [0.30 ; 0.60 ] CanSino phase 3, 2021 1 0% 21,250 NA not evaluable intracranial hemorrhage detailed results Li J, 2022 1.03 [0.02; 52.46]
1.03 [0.02 ; 52.46 ] Li J, 2022 1 0% 299 NA not evaluable ischemic strokedetailed results CanSino phase 2 (Zhu), 2020 0.33 [0.01; 16.67]
Li J, 2022 1.03 [0.02; 52.46]
0.58 [0.04 ; 9.36 ] CanSino phase 2 (Zhu), 2020, Li J, 2022 2 0% 807 NA not evaluable Myocardial infarction detailed results CanSino phase 2 (Zhu), 2020 0.33 [0.01; 16.67]
Li J, 2022 1.03 [0.02; 52.46]
0.58 [0.04 ; 9.36 ] CanSino phase 2 (Zhu), 2020, Li J, 2022 2 0% 807 NA not evaluable pulmonary embolismdetailed results CanSino phase 2 (Zhu), 2020 0.33 [0.01; 16.67]
Li J, 2022 1.03 [0.02; 52.46]
0.58 [0.04 ; 9.36 ] CanSino phase 2 (Zhu), 2020, Li J, 2022 2 0% 807 NA not evaluable serious adverse events (SAE), anydetailed results CanSino phase 3, 2021 1.40 [0.62; 3.15]
1.40 [0.62 ; 3.15 ] CanSino phase 3, 2021 1 0% 36,717 NA not evaluable severe adverse eventsdetailed results CanSino phase 3, 2021 11.00 [1.42; 85.22]
11.00 [1.42 ; 85.22 ] CanSino phase 3, 2021 1 0% 36,717 NA not evaluable venous thromboembolism detailed results Li J, 2022 1.03 [0.02; 52.46]
1.03 [0.02 ; 52.46 ] Li J, 2022 1 0% 299 NA not evaluable systemic adverse reaction, any, dose 1detailed results Out of scale Fengcai, 2021 20.24 [10.60; 38.63]
20.24 [10.60 ; 38.63 ] Fengcai, 2021 1 0% 430 NA not evaluable systemic adverse reaction, any, dose 2detailed results Fengcai, 2021 4.39 [2.05; 9.41]
4.39 [2.05 ; 9.41 ] Fengcai, 2021 1 0% 430 NA not evaluable 0.2 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-21 05:09 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 89
- treatments: 760
- roots T: 290